Back to top
more

Juno Therapeutics, Inc. (JUNO)

(Real Time Quote from BATS)

$86.96 USD

86.96
NA

+0.09 (0.10%)

Updated Mar 5, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

    Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

    Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

      Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck

        Merck to Buy Australian Firm to Boost Immunotherapy Pipeline

        Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.

          What's in Store for Juno Therapeutics (JUNO) in Q4 Earnings?

          Although Juno Therapeutics' (JUNO) product portfolio lacks revenue figures, the company's most advanced pipeline candidates, JCAR017 and JCAR014, might still drive the stock in Q4.

            Celgene Reports Positive Data on Dermatology Drug Otezla

            Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.

              Sweta Killa headshot

              5 Best-Performing Stocks of the Top ETF of January

              Inside the top performing stocks of the top biotech ETF of January.

                Sanghamitra Saha headshot

                Biotech ETF (XBI) Hits New 52-Week High

                This biotech ETF hit a new 52-week high. Are more gains in store for this fund?

                  Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid

                  Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.

                    Tirthankar Chakraborty headshot

                    Play Biotech Buyout Frenzy With These 2 Solid Funds

                    More deals are expected to be signed in the biotech space, courtesy of the tax reform bill that allows companies to repatriate cash piled overseas

                      Bluebird Up on Buyout Speculation After Celgene/Juno Deal

                      Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.

                        Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion

                        Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.

                          Sweta Killa headshot

                          Biotech ETF (BBC) Hits New 52-Week High

                          This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

                            Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?

                            Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.

                              Gilead Collaborates with Pfizer for Yescarta Combo Study

                              Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.

                                Juno Hits 52-Week High on Celgene's Rumored Buyout Interest

                                Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.

                                  Company News For Jan 18, 2018

                                  Companies In The News are: TIF,CSX,JUNO,CELG,FAST

                                    Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA

                                    Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.

                                      Is Celgene (CELG) Looking to Take Over Juno Therapeutics?

                                      There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.

                                        Celgene Provides 2017 Preliminary Results & 2018 View

                                        Celgene Corporation (CELG) provided preliminary results for 2017 and upbeat guidance for 2018. The company suffered a few setbacks of late and is looking to bolster its pipeline.

                                          4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio

                                          Celldex stock has been performing well for the last six months and the momentum is likely to continue in the near term.

                                            What Drives Juno Therapeutics (JUNO) Above 150% This Year

                                            We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.

                                              CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More

                                              The CAR-T therapy space has been in spotlight since Aug 2017 and the recent ASH meeting had further put focus on the same.

                                                Juno Reports Additional Data on CAR-T Therapy, Shares Drop

                                                Juno (JUNO) releases additional results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate, JCAR017.

                                                  Bluebird's Shares Jump on Strong Data for CAR-T Therapy

                                                  bluebird (BIRD) announced updated results from the ongoing phase I study of its chimeric antigen receptor T-cell (CAR-T) therapy candidate- bb2121.